Can Mounjaro Cause Miscarriage? The Evidence and What It Means for You

What the prescribing evidence actually says about pregnancy risk

No human clinical trial has studied what happens when pregnant women take tirzepatide. That's not an oversight, it's standard practice to exclude pregnant participants from early-phase trials to avoid harm. The data we do have come from animal studies conducted during the drug's development, and those studies are the reason for the current guidance.

In reproductive toxicology studies in animals, tirzepatide was associated with reduced fetal growth, structural abnormalities and pregnancy loss at exposures that overlapped with the therapeutic range used in humans. These findings were sufficient for regulators to classify tirzepatide as not recommended in pregnancy, and for the NHS medicines page on tirzepatide to state clearly that the medicine should not be used during pregnancy. Whether the same effects would occur in humans, and at what dose threshold, cannot be determined from animal data alone. That uncertainty is exactly why the precautionary guidance exists.

It is also worth noting that obesity itself carries well-documented risks in pregnancy, including a higher rate of miscarriage, gestational diabetes and preeclampsia. This means that if a miscarriage occurs in someone who was taking Mounjaro, attributing it solely to the medicine is not straightforward. That complexity doesn't reduce the importance of stopping treatment, it means the clinical picture is genuinely complicated, and a prescriber needs to be involved.

Why UK guidance says to stop before you start trying

The Mounjaro Summary of Product Characteristics, and the clinical guidance that UK prescribers follow, recommend stopping tirzepatide before attempting to conceive. There is also a wash-out period advised before trying, because tirzepatide remains in the body for some time after the last injection, and the period of early embryonic development is thought to be particularly sensitive.

NHS England's guidance on weight-management injections reflects this consistently: contraception is recommended throughout treatment, and women who want to become pregnant should plan a supervised stop with their prescriber. This isn't a minor footnote. It's one of the more firmly stated points in the guidance, and it applies regardless of which dose you're taking or how long you've been on treatment.

The contraception point deserves particular attention. Tirzepatide slows gastric emptying, which can reduce the absorption of oral contraceptive pills. UK guidance is specific: women on the pill should add a barrier method for the first four weeks of starting Mounjaro, and for four weeks after any dose increase. This is distinct from the guidance for semaglutide, where no equivalent reduction in pill effectiveness has been documented. If you're relying on the pill alone while taking Mounjaro, speak to a prescriber, the NHS England weight-management injections page sets this out plainly.

If you're pregnant now, or think you might be

If you've discovered you're pregnant while taking Mounjaro, stop taking it and contact your prescriber and GP the same day. Don't wait for your next scheduled clinical review. That advice holds even if you feel well, even if you're early in pregnancy, and even if you're unsure.

If you're uncertain whether what you're feeling might point to a pregnancy, a standard over-the-counter test is the sensible first step. A positive result means the conversation with your prescriber needs to happen today, not after you've researched the topic further online. If you're already several weeks into a pregnancy and you've been taking Mounjaro throughout, your GP or midwife will want to know, it's relevant clinical information for your antenatal care, and early disclosure helps them support you properly.

It's completely understandable to feel anxious if you find yourself in this position. The honest answer is that no one can tell you with certainty what the exposure means for your specific situation. What a prescriber can do is help you understand the timeline, document what happened, and make sure you're being looked after in the right place. That matters more right now than any amount of online reading, including this page.

For a broader picture of what Mounjaro affects beyond this specific question, the full overview of effects associated with Mounjaro covers the wider side-effect profile in detail. The Mounjaro treatment page also has background on how tirzepatide is used in UK weight management, and our cost context page is there if you're assessing your options more broadly. Questions about specific conditions and Mounjaro (from gut symptoms to circulatory concerns, and including whether Mounjaro can cause MS) are answered separately in the same series.

What to do if you're planning a pregnancy in the future

If you're not currently pregnant but know you want to be at some point, this is a conversation worth having with your prescriber before the decision becomes urgent. There's no single answer to how far in advance you should stop Mounjaro, that depends on how long you've been taking it, which dose you're on, and your overall health picture. What's clear is that stopping abruptly without a plan is not the best approach; a managed wind-down, ideally with continued dietary and lifestyle support, puts you in a better position.

Weight management during and after treatment is a genuine clinical conversation, not just an afterthought. The biology of weight regain after stopping GLP-1 medicines is real, and for many people, planning a pregnancy is also a moment to think about what sustainable support looks like. Our weight-loss treatment overview covers the range of options available through a regulated UK service. If you'd like to talk through your specific situation with a clinician, the right place to start is a free consultation with our prescribers, they can review your history and advise on timing. You can speak to our prescribers here.